Stay updated on Extension Study for KarXT Safety in Schizophrenia Clinical Trial

Sign up to get notified when there's something new on the Extension Study for KarXT Safety in Schizophrenia Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Extension Study for KarXT Safety in Schizophrenia Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The page's related topics now include Schizophrenia and MedlinePlus Genetics, and the revision tag was updated from v3.5.3 to v3.5.4.
    Difference
    0.1%
    Check dated 2026-05-15T02:17:30.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    Schizophrenia, related topics, and MedlinePlus Genetics references were removed from the page, changing how the study’s condition and related educational resources are presented to users. This affects the contextual framing of the trial without altering the underlying data.
    Difference
    0.0%
    Check dated 2026-05-07T22:51:15.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.5.2 to v3.5.3, indicating a new release/version of the page. This change reflects a minor update to the page's release notes/history without altering the study details visible to users.
    Difference
    0.0%
    Check dated 2026-04-30T18:42:53.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    Added a link section for **Schizophrenia** related topics, including **MedlinePlus Genetics**.
    Difference
    0.0%
    Check dated 2026-04-23T14:49:15.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2. No other content appears to be affected.
    Difference
    0.0%
    Check dated 2026-04-16T10:47:58.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    Sponsor attribution updated to Karuna Therapeutics, Inc., a Bristol Myers Squibb company, replacing Karuna Therapeutics.
    Difference
    0.1%
    Check dated 2026-04-02T00:33:34.000Z thumbnail image

Stay in the know with updates to Extension Study for KarXT Safety in Schizophrenia Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Extension Study for KarXT Safety in Schizophrenia Clinical Trial page.